RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

NCT06798896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Onset Seizures

Interventions

DRUG: SPN-817
DRUG: Placebo

Sponsor

Supernus Pharmaceuticals, Inc.